Abstract:【Objective】To investigate the changes of the inflammation factor levels and the clinical effect of noninvasive bi-level positive airway pressure (BiPAP) combined with respiratory stimulant treatment on COPD patients with mild to moderate pulmonary encephalopathy. 【Methods】A total of 80 patients with COPD and mild to moderate pulmonary encephalopathy at the Central Hospital of Jiangjin District between December 2013 and December 2015 were randomly divided into the observation group (n=40) and the control group (n=40). Patients in both groups received routine supportive treatments in addition to BiPAP ventilation while the observation group was treated with respiratory stimulant. A variety of the indicators (PaO2, PaCO2,SaO2, RR, HR) was recorded before and after treatment in two groups. 【Results】After 24 hours of treatment, PaO2 and SaO2 in the observation group improved significantly more than those in the control group (P<0.05). PaCO2, RR and HR were significantly lower in the observation group than in the control group, and aeration time, consciousness recovery time, hospital stay and tracheal intubation rate were significantly shorter (all P<0.05). The levels of IL-6, IL-8 and IL-10 in the observation group were significantly lower than those in the control group (all P<0.05).The effective rate of the observation group was 90.0%, which was higher than that of the control group (47.5%); it showed statistical significance (P<0.05) . 【Conclusion】Application of BiPAP combined with respiratory stimulants is an effective treatment for COPD patients with pulmonary encephalopathy. It can reduce the tracheal intubation rate and shorten the hospitalization time.